Shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Free Report) have received a consensus rating of “Hold” from the seventeen analysts that are currently covering the company, Ratings reports. One ...

Building on a record year of Chromium product releases in 2024, 10x Genomics announced plans to enable high-performance, mega-scale single cell analysis with improved efficiency and ease of use.

10x Genomics, Inc., a life science technology ... and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic ...

The certified compatibility is between 10x Genomics’ latest Chromium Universal GEM-X 3’ and GEM-X 5’ single-cell chemistries — which enhance sensitivity while reducing cost per cell — and Oxford ...

10x Genomics' instruments sales fell to $24.35 million from $38.4 million a year ago. This included $10.93 million from Chromium instruments and $13.43 million from Spatial instruments.

and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

10x Genomics specializes in developing and manufacturing genomics analysis technologies, with a focus on single-cell and spatial genomics. The company's product portfolio includes the Chromium and ...